PharmaJet said today it inked a global license agreement with South Korean bioptherapeutics company Genexine to develop and commercialize DNA vaccines using PharmaJet’s needle-free injection system.
Through the deal, Genexine will gain access to use both the PharmaJet Stratis and Tropis devices for their Phase I and Phase IIa human clinical studies. The deal also includes a provision for a possible expansion into Phase III clinical trials and commercialization.
Steve MacMillan took over as CEO of Hologic in 2013, drawing on his experience at medtech titans like Stryker and Johnson & Johnson. Since then, Hologic has grown into a $3 billion business.
At DeviceTalks Boston, MacMillan will provide exclusive insights into the Massachusetts-based company and its evolving definition of women's healthcare. You don't want to miss it!
Use code WOMENSHEALTH to save an additional 10%.